Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2159 - Rapid and objective CT-scan prognostic scoring identifies patients with long-term clinical benefit on phase I trials


09 Oct 2016


Poster display


Laurent Dercle


Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378


L. Dercle1, S. Ammari1, S. Champiat1, C. Massard2, C. Ferte3, M. Texier3, E. Lanoy2, L. Taihi3, R. Seban3, S. Aspeslagh4, S. Antoun4, L. Mahjoubi4, N. Kamsu-Kom4, C. Robert4, A. Marabelle4, M. Schlumberger5, J. Soria4, S. Postel-Vinay4

Author affiliations

  • 1 Nuclear Medicine, Institut de Cancérologie Gustave Roussy, 94800 - Villejuif/FR
  • 2 Drug Development Department, Institut Gustave Roussy, Villejuif/FR
  • 3 Département De Médecine Oncologique, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 4 Drug Development Department (ditep), Institut Gustave Roussy, 94800 - Villejuif/FR
  • 5 Nuclear Endocrinology, Institut Gustave Roussy, Villejuif/FR


Abstract 2159


Drugs targeting programmed death receptor-1 and its ligand PD-L1 (aPD(L)1) have shown activity in multiple malignancies. Considering their novel mechanism of action, whether traditional prognostic scores also apply to patients receiving aPD(L)1 is unknown. We investigated whether a baseline 3-points (pts) CT-scan (PS3-CT) score and a 7-pts prognostic score (PS7) allowed identifying long-term survivors on aPD(L)1 as compared to molecularly targeted agents (MTA).


We reviewed all consecutive patients enrolled in phase I (PhI) trials evaluating aPD(L)1 between 12/2011 and 07/2015, and in PhI trials evaluating MTA between 03/2008 and 07/2012. PS3-CT was calculated using high tumor burden (TB > 9 cm), low-skeletal muscle index (SMI< 53 cm2.m-2) and non-pulmonary visceral metastases (NPVM) (1 pt each). PS7 was calculated by adding performance status >1, low albumin, high LDH and >2 metastases (1 pt. each). Effect on overall survival (OS) of each parameter was tested using Kaplan Meier and Multivariate Cox analyses.


461 patients (251 receiving aPD(L)1 and 210 receiving MTA) were included. Patients characteristics were comparable in both groups, excepted for melanoma patients (40% and 5% of the patients in the aPD(L)1 and MTA groups, respectively). PS3-CT was a significant independent predictor of OS in the aPD(L)1 (HR = 1.39 [95%CI = 1.07-1.81]; p = 0.01) and MTA (HR = 1.35 [95%CI = 1.08-1.68]; p = 0.01) groups, when compared to the Royal Marsden Hospital, Barbot and AJCC scores. High-TB and low-SMI were independent predictors of OS (HR = 2.00 [95%CI = 1.38-2.88], p 


Objective and rapid risk scoring based on three CT-scan parameters allows identifying patients with prolonged OS on anti-PD(L)1 and MTA PhI trials, independently from conventional clinico-biological prognostic scores.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings